Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome

  • Authors:
    • Susumu Tanaka
    • Hirohiko Kuratsune
    • Yoh Hidaka
    • Yukiko Hakariya
    • Ke-Ita Tatsumi
    • Toru Takano
    • Yuzuru Kanakura
    • Nobuyuki Amino
  • View Affiliations

  • Published online on: August 1, 2003     https://doi.org/10.3892/ijmm.12.2.225
  • Pages: 225-230
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The disturbance of the central nervous system and immunological abnormalities have been suggested in patients with chronic fatigue syndrome (CFS). We focused on immunological abnormalities against neurotransmitter receptors in CFS. Using a sensitive radioligand assay, we examined serum autoantibodies to recombinant human muscarinic cholinergic receptor 1 (CHRM1), mu-opioid receptor (OPRM1), 5-hydroxytryptamine receptor 1A (HTR1A), and dopamine receptor D2 (DRD2) in patients with CFS (n=60) and results were compared with those in patients with autoimmune disease (n=33) and in healthy controls (n=30). The mean anti-CHRM1 antibody index was significantly higher in patients with CFS (p<0.0001) and autoimmune disease (p<0.05) than that in healthy controls, and positive reaction was found in 53.3% of patients with CFS. Anti-OPRM1 antibodies, anti-HTR1A antibodies, and anti-DRD2 antibodies were found in 15.2, 1.7, and 5.0% of patients with CFS, respectively. Anti-nuclear antibodies were found in 56.7% (34/60) of patients with CFS, but anti-nuclear antibody titers did not correlate with the activities of the above four autoantibodies. The patients with positive autoantibodies to CHRM1 had a significantly higher mean score (1.81) of ‘feeling of muscle weakness’ than negative patients (1.18) among CFS patients (p<0.01). Higher scores on ‘painful node’, ‘forgetfulness’, and ‘difficulty thinking’ were also found in CFS patients with anti-CHRM1 antibodies but did not reach statistical significance. In conclusion, autoantibodies to CHRM1 were detected in a large number of CFS patients and were related to CFS symptoms. Our findings suggested that subgroups of CFS are associated with autoimmune abnormalities of CHRM1.

Related Articles

Journal Cover

August 2003
Volume 12 Issue 2

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tanaka S, Kuratsune H, Hidaka Y, Hakariya Y, Tatsumi K, Takano T, Kanakura Y and Amino N: Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. Int J Mol Med 12: 225-230, 2003.
APA
Tanaka, S., Kuratsune, H., Hidaka, Y., Hakariya, Y., Tatsumi, K., Takano, T. ... Amino, N. (2003). Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome. International Journal of Molecular Medicine, 12, 225-230. https://doi.org/10.3892/ijmm.12.2.225
MLA
Tanaka, S., Kuratsune, H., Hidaka, Y., Hakariya, Y., Tatsumi, K., Takano, T., Kanakura, Y., Amino, N."Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome". International Journal of Molecular Medicine 12.2 (2003): 225-230.
Chicago
Tanaka, S., Kuratsune, H., Hidaka, Y., Hakariya, Y., Tatsumi, K., Takano, T., Kanakura, Y., Amino, N."Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome". International Journal of Molecular Medicine 12, no. 2 (2003): 225-230. https://doi.org/10.3892/ijmm.12.2.225